Health

DEA Adds Specific Schedule I Listing for Hexahydrocannabinol (HHC)

🇺🇸United States··Final Rule·Low Impact·View source ↗

AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.

🇬🇧 English

Adds hexahydrocannabinol, known as HHC, to the DEA’s Schedule I controlled substances list under its own name and drug code, 7220. DEA says this does not newly ban HHC because it was already treated as a Schedule I substance as a synthetic tetrahydrocannabinol. The practical effect is clarity and administration. Businesses, labs, manufacturers, distributors, and retailers should treat synthetic HHC, including HHC made through chemical conversion from hemp-derived materials, as a Schedule I controlled substance. DEA-registered manufacturers may now receive HHC-specific production and procurement quotas instead of using the broader tetrahydrocannabinols code.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.

Key Changes

  • Creates a separate Schedule I listing for HHC under DEA drug code 7220
  • Confirms that synthetic HHC remains a Schedule I controlled substance
  • Allows DEA to set HHC-specific production and procurement quotas for registered manufacturers

Obligations

What this law requires

critical

Treat 6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-1-ol, also known as hexahydrocannabinol or HHC, as a Schedule I controlled substance under DEA drug code 7220.

businesses handling HHClaboratories handling HHCmanufacturers handling HHCdistributors handling HHCretailers handling HHC
Effective May 4, 2026
operational
critical

Do not manufacture, distribute, dispense, possess, import, or export synthetic HHC unless authorized under the Controlled Substances Act requirements applicable to Schedule I substances.

manufacturersdistributorsretailerslaboratoriesresearch organizationsimporters and exporters
Ongoing; HHC remains Schedule I, with specific listing effective May 4, 2026
prohibition
critical

Do not treat HHC produced through chemical conversion from hemp-derived materials as exempt “tetrahydrocannabinols in hemp”; such chemically converted HHC is considered synthetically produced and remains controlled as Schedule I.

hemp-derived cannabinoid manufacturerscannabis product manufacturerslaboratoriesdistributorsretailers
Ongoing; specific listing effective May 4, 2026
operational
high

DEA-registered manufacturers of HHC must use the HHC-specific DEA drug code 7220 for HHC-related manufacturing and procurement quota administration, rather than relying on the broader tetrahydrocannabinols drug code.

DEA-registered manufacturers of HHC
Effective May 4, 2026
operational
high

DEA-registered manufacturers of HHC must obtain and operate within DEA manufacturing and procurement quotas applicable to HHC under its separate Schedule I listing and drug code 7220.

DEA-registered manufacturers of HHC
Effective May 4, 2026
licensing

Affected Parties

DEA-registered controlled substance manufacturersCannabinoid and hemp-product businesses+3 more…

Tags

DEA,HHC,controlled substances